Back to Talentmark News
NOV 23

Event: Investment and Exit strategies for Life Sciences SMEs

Event: Investment and Exit strategies for Life Sciences SMEs

Talentmark is hosting an event to celebrate its 40th anniversary with an evening of networking and industry debate at the National Liberal Club, Whitehall Place, London SW1A 2HE, 020 7930 9871

Commemorating Talentmark's 40 years of dedicated service to the life science industry, the event will provide plenty of opportunity to network with a broad cross-section of international industry colleagues. The evening will focus on a panel-led discussion addressing the issues facing life sciences companies seeking investment and considering potential exit strategies.




18.00 Registration and Drinks
19.00 Panel Discussion
20.30 Networking Drinks and Canapes

We are delighted to announce that our panel will include:

Dr Anthony Hartley is an Executive Director in the Healthcare Investment Banking Group at Morgan Stanley, where he focuses on pharmaceutical and biotechnology companies on a pan-European basis.
Anthony has spent over 10 years in healthcare investment banking, predominantly focused on the European biotech and pharmaceutical sectors, and before joining Morgan Stanley previously worked for Lehman Brothers Europe and Credit Suisse First Boston.
He has completed and advised on numerous acquisitions and corporate finance transactions in both the public and private biotech sectors including advisory transactions for Actelion, Addex Pharmaceuticals, Ark Therapeutics, AstraZeneca, BioXell, ESBATech, GPC Biotech, Jerini, ProStrakan, Protherics, Novartis, Q-Med, Roche, Serono, Shire and SkyePharma.
Anthony holds a Doctorate (D.Phil) in Pharmacology from The University of Oxford, and an MBA (Distinction) from Manchester Business School. Prior to his career in investment banking, Anthony spent a total of 7 years in the pharmaceutical industry working in a variety of research and commercial roles at Pfizer, GlaxoSmithkline and AstraZeneca.

Sam Fazeli is the director of Bloomberg Industries (BI) for the EMEA region. he is also a senior Pharmaceuticals analyst for BI. Sam has covered the drug industry as an investment banking analyst for over 13 years, latterly at Piper Jaffray (2005-2010). Sam has a PhD in Pharmacology from the University of London.

Stuart Swanson is currently a Consultant to Valeant Pharmaceuticals International, Inc. which bought PharmaSwiss SA effective March 11, 2011.
Swanson joinined PharmaSwiss shortly after its founding in 2001, and was one of two founder partners. Swanson has assumed a number of leadership roles in the company, including both operational management and driving corporate strategy, investor relations and business development.. At the time of sale to Valeant, Swanson was Board Member and President of Corporate Development.
Prior to joining PharmaSwiss, Swanson held a series of senior operational and regional HQ positions for Bristol-Myers Squibb (BMS) in Central Europe and Israel. Prior to BMS, Swanson was Pfizer's first General Manager in Russia & CIS, opening Pfizer's first affiliates in Russia, Kazakhstan, Uzbekistan and Turkmenistan. Swanson began his career as a US diplomat, serving in Pakistan and Leningrad / St. Petersburg.
Swanson bases out of London.

Dr. Nigel Parker has spent over 30 years in the International Pharmaceutical and Biotech sector. Holding CEO and Board Director positions in Public and Private Companies, he has successfully negotiated IPO's, Secondary Offerings, numerous Private Equity financings and M and A's. A Descartes Prize for Science finalist in 2004, he has been a pioneer of gene based medicines from early preclinical work days through the clinic and the Regulatory processes, achieving a number of world firsts on the way. Dr Parker is now Chairman of FKD Therapies, Finland and Gschäftsfürer of Wölbern Invest Private Equity, Germany.

Dr Hamish Cameron joined SVLS in 2008 as a Venture Partner and has been Interim CEO at X2-Pharma and Delenex Therapeutics and Chief Commercial Officer at ESBATech. Before joining SVLS, Dr Cameron was CEO of Cambridge Antibody Technology ("CAT"). Prior to that, he held a series of senior R&D positions at AstraZeneca/Zeneca including Head of the Cardiovascular Therapy Area, Senior Vice-President Medical Research and was a member of the R&D Leadership Team. Dr Cameron started his industry career with Janssen, after working in clinical practice and research in the UK.
Hamish was trained as a physician and holds MBBS and BSc (Hons) Pharmacology degrees from the University of London. He is a member of the UK Royal College of Physicians and a Fellow and past Board member of the Faculty of Pharmaceutical Medicine.

Barry Clare co-founder of Clarat Partners LLP will act as chair. Barry has over twenty years experience in healthcare having served on the board of Boots and most recently as chairman of several privately equity funded healthcare companies, including remote diagnostics, medical devices, biotech and OTC medicines. He has unique experience of publicly and privately owned companies, including Standard Chartered Bank, and has worked extensively with private equity and venture funds, to commercialise new technology in healthcare.